权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Oxidative Stress in Chronic Beryllium Disease

针对慢性铍病的氧化应激

基本信息

批准号：
8450168
负责人：
Brian J Day
金额：
$ 33.66万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-01 至 2015-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8450168
关键词：
Acetylation Address Anti-Inflammatory Agents Anti-inflammatory Antigens Antioxidants Beryllium Biochemical Bronchoalveolar Lavage CD4 Positive T Lymphocytes Cell Proliferation Cells Chronic Chronic berylliosis Clinical Research Couples Cysteine DNA Double-Blind Method Drug usage Equilibrium Flow Cytometry Functional disorder Glucocorticoid Receptor Goals Granuloma Granulomatous HDAC2 gene Heat shock proteins Histones Homeostasis Human Hypersensitivity Immune response In Vitro Inflammation Inflammatory Interferons Interleukin-2 Lipids Lung Lung Inflammation Lung diseases Mediating Mesalamine Modification Molecular Normal Cell Oxidation-Reduction Oxidative Stress Pathogenesis Pathway interactions Patients Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Phosphorylation Population Prednisone Production Proliferating Property Proteins Randomized Recycling Respiratory physiology Role Salicylic Acids Spirometry Steroids Sulfhydryl Compounds T cell response T-Cell Proliferation T-Lymphocyte TNF gene Testing Therapeutic Effect Thioredoxin Ubiquitination Ulcerative Colitis base capsule cell type cytokine histone acetyltransferase in vivo macrophage nitration novel novel strategies novel therapeutic intervention oxidation placebo controlled study public health relevance pulmonary granuloma research study response secondary outcome stress protein therapeutic target

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this application is to understand the role of oxidative stress as a potential target in the pathogenesis of chronic beryllium disease (CBD). CBD is an inflammatory hypersensitivity lung disease that occurs in over 800,000 beryllium-exposed workers in the US characterized by pulmonary granulomas. The molecular mechanisms by which beryllium regulates the chronic production of lung inflammation and granuloma formation are unknown. We hypothesize that beryllium induces oxidative stress by altering thiol homeostasis which enhances beryllium specific T cells to produce excessive Th1 cytokines and proliferate, two key features of CBD pathophysiology. Three specific aims are proposed to address the hypothesis. Specific aim 1 will examine the mechanisms by which beryllium stimulates oxidative stress in beryllium specific CD4+ T cells by altering thiol redox status. Specific aim 2 will determine whether beryllium-mediated oxidative stress alters the balance between histone acetyltransferase (HAT) and histone deacetyltransferase (HDAC) activities that modulates inflammation and steroid sensitivity in CBD. This aim will test whether beryllium exposure creates oxidative stress that impairs HDAC activity as a mechanism that amplifies inflammation in CBD. Specific aim 3 will examine the potential therapeutic effect of a 5 aminosalicylic acid in CBD subjects. This last aim will assess a novel new therapy in CBD patients that targets beryllium-mediated oxidative stress and inflammation. The proposed experiments elucidate novel mechanisms that explain the excessive cytokine response to beryllium and pinpoint the role of antioxidant imbalance in CBD and mechanistic approaches to treat CBD.

描述（由申请人提供）：本申请的总体目标是了解氧化应激作为慢性铍病（CBD）发病机制中的潜在靶点的作用。CBD是一种炎症性超敏反应性肺病，发生在美国超过800，000名接触铍的工人中，其特征是肺部肉芽肿。铍调节慢性肺部炎症和肉芽肿形成的分子机制尚不清楚。我们假设铍通过改变巯基稳态诱导氧化应激，巯基稳态增强铍特异性T细胞产生过量的Th1细胞因子并增殖，这是CBD病理生理学的两个关键特征。提出了三个具体目标来解决这个假设。具体目标1将检查铍通过改变硫醇氧化还原状态来刺激铍特异性CD4 + T细胞中的氧化应激的机制。具体目标2将确定铍介导的氧化应激是否改变组蛋白乙酰转移酶（HAT）和组蛋白脱乙酰转移酶（HDAC）活性之间的平衡，从而调节CBD中的炎症和类固醇敏感性。这一目标将测试铍暴露是否会产生氧化应激，损害HDAC活性，作为放大CBD炎症的机制。具体目标3将检查5氨基水杨酸在CBD受试者中的潜在治疗效果。最后一个目标将评估CBD患者的一种新疗法，该疗法针对铍介导的氧化应激和炎症。拟议的实验阐明了新的机制，解释了细胞因子对铍的过度反应，并确定了CBD中抗氧化剂失衡的作用和治疗CBD的机制方法。